DMD Phase 2 Results in Q4 = Potential 5000% Gem, page-243

The real problem with Sarepta or potentially and the one that would play badly for ANP is them still needing to show the long awaited data on Exondy51 and the confirmatory trial that was part of the agreement with FDA when being granted break-through given it didn't actually show much and was approved on such a small trial. ANP is also hoping to be able to push through on a small trial basis so it really needs Sarepta to deliver there and FDA to keep it on market - or they're unlikely to do it again ? ​

https://endpts.com/after-a-posse-of...on-a-critical-fda-decision/[/BCOLOR][/BCOLOR]​

https://sp-foundation.org/news-reso...-already-on-market[/BCOLOR][/BCOLOR][/BCOLOR]​